Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.24
- Piotroski Score 3.00
- Grade Buy
- Symbol (OCUP)
- Company Ocuphire Pharma, Inc.
- Price $1.29
- Changes Percentage (0%)
- Change -$0
- Day Low $1.28
- Day High $1.33
- Year High $3.76
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.47
- Trailing P/E Ratio -3.6
- Forward P/E Ratio -3.6
- P/E Growth -3.6
- Net Income $-9,986,000
Income Statement
Quarterly
Annual
Latest News of OCUP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Investors are attracted to unprofitable companies due to potential high returns. Ocuphire Pharma's cash burn analysis reveals a long cash runway despite falling revenue, indicating its ability to mana...
By Yahoo! Finance | 1 month ago